Lexington, KY – One of the nation’s leaders in the fight against degenerative joint disease in horses, Adequan® (polysulfated glycosaminoglycan), has renewed their commitment with the United States Equestrian Federation (USEF) in a multi-faceted sponsorship. In addition, Adequan® remains as “The Official Joint Therapy of the USEF.”

Luitpold Pharmaceuticals, manufacturer of the flagship equine health product, Adequan®, continues their commitment as title sponsor for three USEF championships for the 2007 competition season: the 2007 USEF National Open Reining Championship and the 2007 USEF National Pony Jumper Championships, both in Lexington, Kentucky, and the 2007 USEF National Junior Jumper Championships in Harrisburg, Pennsylvania.

“We are pleased to continue our solid partnership with Adequan,” said USEF Chief Executive Officer John Long. “With equestrian sports, keeping horses fit and sound is essential. By using Adequan, a horse’s performance potential can be maximized.”

Due to the rigors of competition, many performance horses suffer from joint disease. Adequan® is designed to help treat the underlying cause of the problem and break the cycle of damage, while reducing pain and inflammation.

“We continue to share the vision of the USEF to promote the pursuit of excellence and the welfare of the horses,” said Allyn Mann, Senior Manager of the Animal Health Division at Luitpold. “With the only disease-modifying joint disease treatment of Adequan® i.m., USEF members can help keep their horses performing at the top of their game. We appreciate that USEF members have shown confidence in our brand, our product and our results. They know from experience that we understand the needs of performance horses and that we support the devoted equestrians and horses throughout the industry.”

To learn more about the causes, effects and treatments for equine degenerative joint disease, Adequan® offers a free CD, “Balanced joints. Sound horse.” To request this free educational video, call 1-800-974-9247. For additional information about Adequan®, visit www.adequan.com.
There are no known contraindications to the use of intramuscular polysulfated glycosaminoglycan or PSGAG in horses. Studies have not been conducted to establish safety in breeding horses.

For more information, please contact Stacey Meier, Director of National Marketing at (859) 225-6974 or via email at [email protected].